The facility, slated to be GMP-ready in 2027, will house one of Japan’s largest single-use bioreactor systems for mammalian production, according to the company.
The CDMO added cleanrooms, quality control labs, and digital systems to support commercial-scale production, validation, and release of cell therapy products.
